KORU Medical Systems Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, everyone, and thank you for joining us at this year's Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. My name is Caitlin Roberts, and I'm one of the medical device analysts here at Canaccord. I'm pleased to be joined this morning by KORU Medical, a medical device company focused on innovative portable solutions for the drug delivery market. With me today is Adam Kalbermatten, CEO, and Tom Adams, CFO. Before we begin, I want to remind everyone of any relevant disclosures, which can be found in our conference and our firm website. We'll begin with a Q&A, a fireside chat with the KORU team, and I'll try to leave a couple minutes at the end for any questions from the audience. Maybe we can get started with the Q3, since you just reported results last night.
Bit of a noisy quarter from a comp perspective, but maybe just speak to how the business performed versus your expectations and what gives you confidence in achieving the guidance for this year.
Absolutely. Good morning, everybody. Maybe a quick background before I dig into the specific question on KORU and who we are. KORU Medical is a company focused on large volume subcutaneous drug delivery. Over 90% of our business is supporting immunoglobulin patients who have to self-administer medications on a weekly and monthly basis. We just reported earnings for our third quarter yesterday. To Caitlin's question, we just came out of a pretty solid quarter that we had for Q3. In that quarter, not only we deliver strong growth for the year, we had 11% growth on the quarter, but we had our second consecutive quarter of EBITDA positive earnings. So we were very impressed with our results. Outside of that, we had a few instrumental things that we hinted at in our previous quarter that we were continuing to execute our expansion internationally.
We'll get into that a little bit later, but we did sign some new agreements, and we were able to overcome some of those challenges that we were thinking about that we really needed to make a progress on, so that as we got to Q4, we set ourselves up for a solid close to the year.
Great. Adam, you joined as CEO recently. Maybe just as you settle further into the role, talk about how you are seeing the business and maybe your vision going forward.
Yeah, absolutely. When I joined KORU, I joined about a year and a half ago, and joined the company coming from the last 20 years in drug delivery. A lot of the work that I had previously done was kind of at the convergence of med tech and pharmaceutical companies, supporting pharmaceutical companies with the administration of their drug assets. Coming to KORU and having 510 marketed and approved products for the delivery of immunoglobulin therapies is a great basis for us as we look at kind of the larger shifts in pharmaceuticals that are continuing to move to subcutaneous delivery, but also shifting care out of hospitals, out of infusion centers, and into the home. For me, that was a great basis to continue to build on.
At KORU, what we are now focused on is not only growing within our core, both domestically and internationally with immunoglobulin patients, but also bringing additional therapies on label, which span into other rare disease indications, potentially oncology, and other areas where pharmaceutical companies are looking to enable patients to self-administer their medications.
Great. I understand it is not yet 2027, but if you could provide investors some framework of how to start thinking about next year and maybe the cadence of the top and the bottom lines.
Absolutely. So we're not specifically guiding on where we're going to be in 2027 financially, but we do have a lot of core elements of our strategy that are continuing to progress. So domestically, we continue to outpace the market with our growth. The market's growing 8%-10% a year. We're growing a bit above that in the mid-teens. We've been doing that kind of year-on-year the past few years. Internationally, we continue to expand above market growth rates as well. We're entering new countries and continuing to sign new sales and distribution agreements across the board. That's what I referred to a little bit earlier of what we executed in the third quarter here.
We look at that providing a lot of the basis for us to continue to grow as not only the fourth quarter comes, but as we look into 2027 and we're capturing those new patient starts. We're also really excited. We have a new product that we've been developing for the past few years called our Freedom360. It's a product that's focused on satisfying some of the unmet needs patients have, specifically around end-of-dose notifications and having administrations that require multiple prefilled syringe formats so that they could more easily interchange the formats and reduce their overall administration time. So we're really excited about what's coming in 2027. We have a number of pipeline programs with pharmaceutical partners that continues to expand and make progress. We highlighted some of those yesterday.
A lot of really good, exciting things to think about that are going to translate into revenue over the next 12 to 18 months.
Great. You had this year, in addition to your core business with RYSTIGGO, and on the Q3 call, you talked about three spec pharmas now dispensing RYSTIGGO. Maybe speak to the contribution that the product is making to core revenues and where that can go from here.
Absolutely. In Q3, as Caitlin Roberts just mentioned, we had three specialty pharmacies that completed their clinical evaluations and selected the KORU system for the administration of UCB's RYSTIGGO drug. This is an exciting one because it is a drug outside of immunoglobulin therapy, and it is kind of a proof point of us shifting into other further therapeutic areas. These three specialty pharmacies administer the drug to patients both in ambulatory infusion clinics, but also sending nurses into the home environment to support patients with the self-administration or healthcare worker-facilitated administration. We see it as a nice contributor to our growth as we pick up new patient starts. The drug is in the kind of early stages of its growth phase, so we see that ramping to a potential of $1 million in total revenue over the next few years.
It is a solid addition to our platform, and we look forward to serving those patients as it continues to grow.
Great. Turning to international, it continues to be an important opportunity for you guys, and you noted progress this quarter on non-tender markets in Europe. Maybe provide an explanation of tender versus non-tender markets and why the go-to-market strategy differs between those.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
